Goldman Sachs Says the Crowd Is Wrong on This Beaten-Down Medical Robotics Giant

Intuitive Surgical's stock has declined 26% over the past 12 months due to lower-than-expected margins from its da Vinci 5 launch and tariff-related cost increases. However, Goldman Sachs analyst David Roman maintains a 'buy' rating with a $558 price target (47% upside), arguing the company's long-term prospects remain strong. The da Vinci 5's advanced features like Force Feedback Technology could expand the market and drive higher-margin recurring revenue, while the robotic surgery market remains underpenetrated with significant growth potential.